4.7 Article

Cortical thickness, gray-white matter contrast, and intracortical myelin in first-episode schizophrenia patients treated with long-acting paliperidone palmitate versus oral antipsychotics

Related references

Note: Only part of the references are listed.
Article Psychiatry

Two Neuroanatomical Signatures in Schizophrenia: Expression Strengths Over the First 2 Years of Treatment and Their Relationships to Neurodevelopmental Compromise and Antipsychotic Treatment

Stefan du Plessis et al.

Summary: This study identified two neuroanatomical signatures derived from machine learning that are associated with the neurodevelopmental and treatment-responsive components of schizophrenia. Signature 1 is associated with widespread grey matter volume reductions, while Signature 2 is associated with larger basal ganglia and internal capsule volumes. Patients had higher expression of Signature 1 compared to controls, while Signature 2 expression significantly increased with treatment.

SCHIZOPHRENIA BULLETIN (2023)

Article Psychiatry

Prospective, randomized, multicenter clinical trial evaluating longitudinal changes in brain function and microstructure in first-episode schizophrenia patients treated with long-acting injectable paliperidone palmitate versus oral antipsychotics

Chencai Wang et al.

Summary: Widespread anatomical alterations and abnormal functional connectivity are associated with symptom severity in FES patients. The use of long-acting injectable antipsychotics like PP may be more effective in improving cerebral organization compared to oral antipsychotics (OAP).

SCHIZOPHRENIA RESEARCH (2023)

Article Psychiatry

Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study

T. A. Tishler et al.

Summary: This study investigated the changes in brain intracortical myelin (ICM) volume in the frontal lobe after 9 months of treatment with paliperidone palmitate (PP) versus oral antipsychotics (OAP) in individuals with recent-onset schizophrenia or schizophreniform disorder.

SCHIZOPHRENIA RESEARCH (2023)

Article Psychiatry

The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder

Larry Alphs et al.

Summary: The DREaM study compared the effectiveness of paliperidone palmitate (PP) versus oral antipsychotics (OAP) in delaying time to first treatment failure in participants with recent-onset schizophrenia or schizophreniform disorder. The study highlighted the potential benefits of initiating PP early in the course of schizophrenia.

SCHIZOPHRENIA RESEARCH (2022)

Review Biochemistry & Molecular Biology

Memory and cognition in schizophrenia

J. Y. Guo et al.

MOLECULAR PSYCHIATRY (2019)

Article Clinical Neurology

Subcortical structures and cognitive dysfunction in first episode schizophrenia

Fengmei Fan et al.

PSYCHIATRY RESEARCH-NEUROIMAGING (2019)

Review Behavioral Sciences

Comprehensive review: Computational modelling of schizophrenia

Vincent Valton et al.

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2017)

Article Psychology, Clinical

White matter connectivity disruptions in early and chronic schizophrenia

M. A. Di Biase et al.

PSYCHOLOGICAL MEDICINE (2017)

Article Psychiatry

Dose Equivalents for Antipsychotic Drugs: The DDD Method

Stefan Leucht et al.

SCHIZOPHRENIA BULLETIN (2016)

Article Clinical Neurology

Brain Imaging During the Transition from Psychosis Prodrome to Schizophrenia

Yoonho Chung et al.

JOURNAL OF NERVOUS AND MENTAL DISEASE (2015)

Review Neurosciences

Prefrontal cortex and the dysconnectivity hypothesis of schizophrenia

Yuan Zhou et al.

NEUROSCIENCE BULLETIN (2015)

Article Neurosciences

Assessing intracortical myelin in the living human brain using myelinated cortical thickness

Christopher D. Rowley et al.

FRONTIERS IN NEUROSCIENCE (2015)

Article Neurosciences

Cortical Volume, Surface Area, and Thickness in Schizophrenia and Bipolar Disorder

Lars M. Rimol et al.

BIOLOGICAL PSYCHIATRY (2012)

Article Psychiatry

Risperidone Nonadherence and Return of Positive Symptoms in the Early Course of Schizophrenia

Kenneth L. Subotnik et al.

AMERICAN JOURNAL OF PSYCHIATRY (2011)

Article Psychiatry

Changes in Cortical Thickness During the Course of Illness in Schizophrenia

Neeltje E. M. van Haren et al.

ARCHIVES OF GENERAL PSYCHIATRY (2011)

Article Neurosciences

Mapping Human Cortical Areas In Vivo Based on Myelin Content as Revealed by T1- and T2-Weighted MRI

Matthew F. Glasser et al.

JOURNAL OF NEUROSCIENCE (2011)

Review Psychology, Clinical

Neurocognition in First-Episode Schizophrenia: A Meta-Analytic Review

Raquelle I. Mesholam-Gately et al.

NEUROPSYCHOLOGY (2009)

Article Clinical Neurology

Neurocognitive functioning in patients with first-episode schizophrenia -: Results of a prospective 5-year follow-up study

Margot Albus et al.

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2006)

Article Medicine, General & Internal

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

JA Lieberman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Psychiatry

Identification of separable cognitive factors in schizophrenia

KH Nuechterlein et al.

SCHIZOPHRENIA RESEARCH (2004)

Article Neurosciences

Thinning of the cerebral cortex in aging

DH Salat et al.

CEREBRAL CORTEX (2004)

Review Neurosciences

Schizophrenia: Breakdown in the well-regulated lifelong development and

G Bartzokis

NEUROPSYCHOPHARMACOLOGY (2002)

Article Multidisciplinary Sciences

Measuring the thickness of the human cerebral cortex from magnetic resonance images

B Fischl et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)